LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Momelotinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1339 | 4660 | 0.2869 | 0.0406 |
MDA-MB-231 | Momelotinib | 10 | uM | LJP5 | 72 | hr | 1235 | 574 | 4660 | 0.1228 | -0.3326 |
MDA-MB-231 | Fedratinib | 0.04 | uM | LJP5 | 72 | hr | 1235 | 4389 | 4660 | 0.9400 | 0.9344 |
MDA-MB-231 | Fedratinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4035 | 4660 | 0.8640 | 0.8507 |
MDA-MB-231 | Fedratinib | 0.37 | uM | LJP5 | 72 | hr | 1235 | 3655 | 4660 | 0.7810 | 0.7527 |
MDA-MB-231 | Fedratinib | 1.11 | uM | LJP5 | 72 | hr | 1235 | 2577 | 4660 | 0.5521 | 0.4649 |
MDA-MB-231 | Fedratinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1103 | 4660 | 0.2366 | -0.0590 |
MDA-MB-231 | Fedratinib | 10 | uM | LJP5 | 72 | hr | 1235 | 398 | 4660 | 0.0849 | -0.4514 |
MDA-MB-231 | Trametinib | 0.04 | uM | LJP5 | 72 | hr | 1235 | 1343 | 4660 | 0.2885 | 0.0441 |
MDA-MB-231 | Trametinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 1273 | 4660 | 0.2733 | 0.0149 |
MDA-MB-231 | Trametinib | 0.37 | uM | LJP5 | 72 | hr | 1235 | 1329 | 4660 | 0.2854 | 0.0383 |
MDA-MB-231 | Trametinib | 1.11 | uM | LJP5 | 72 | hr | 1235 | 1305 | 4660 | 0.2798 | 0.0275 |
MDA-MB-231 | Trametinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1275 | 4660 | 0.2737 | 0.0157 |
MDA-MB-231 | Trametinib | 10 | uM | LJP5 | 72 | hr | 1235 | 1285 | 4660 | 0.2751 | 0.0177 |
MDA-MB-231 | Omipalisib | 0.04 | uM | LJP6 | 72 | hr | 1235 | 2003 | 4405 | 0.4543 | 0.2996 |
MDA-MB-231 | Omipalisib | 0.12 | uM | LJP6 | 72 | hr | 1235 | 1518 | 4405 | 0.3449 | 0.1186 |
MDA-MB-231 | Omipalisib | 0.37 | uM | LJP6 | 72 | hr | 1235 | 1155 | 4405 | 0.2623 | -0.0365 |
MDA-MB-231 | Omipalisib | 1.11 | uM | LJP6 | 72 | hr | 1235 | 966 | 4405 | 0.2192 | -0.1265 |
MDA-MB-231 | Omipalisib | 3.33 | uM | LJP6 | 72 | hr | 1235 | 824 | 4405 | 0.1872 | -0.1985 |
MDA-MB-231 | Omipalisib | 10 | uM | LJP6 | 72 | hr | 1235 | 723 | 4405 | 0.1640 | -0.2544 |
MDA-MB-231 | Buparlisib | 0.04 | uM | LJP5 | 72 | hr | 1235 | 4633 | 4660 | 0.9956 | 0.9963 |
MDA-MB-231 | Buparlisib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4457 | 4660 | 0.9554 | 0.9519 |
MDA-MB-231 | Buparlisib | 0.37 | uM | LJP5 | 72 | hr | 1235 | 3987 | 4660 | 0.8539 | 0.8397 |
MDA-MB-231 | Buparlisib | 1.11 | uM | LJP5 | 72 | hr | 1235 | 2909 | 4660 | 0.6221 | 0.5576 |
MDA-MB-231 | Buparlisib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1350 | 4660 | 0.2889 | 0.0435 |